In the world of today with an abundance of preservatives in many foods in addition to processing methods, the incidence of Diabetes and Heart Disease have dramatically increased. Many believe these things done to food items are the culprits that cause all disease.
Because it is nearly impossible for most families to totally avoid these items, we may be facing an epidemic. Physicians cannot do a coronary angiogram, which is an invasive procedure, on every patient to see if they have inflammation in their blood vessels, which may lead to a heart attack, so what is the answer for early diagnosis?
Finding such problems early can save lives and if a test is non-invasive and could be done in a doctor's office, it would be easier to administer and more cost effective. "That day has arrived with the introduction of Corus CAD,a genomic blood test that helps determine if patients have obstructive coronary artery disease (CAD).
Dr. Alan Grossman, a trailblazer in the field of cardiology, was the first physician in the world to order the blood test commercially. Dr. Grossman specializes in non-invasive diagnostic testing and that motivated him to try this innovative new blood test at his office on W Thomas Rd in Phoenix. We spoke with Dr. Grossman to learn more.
During our interview Dr. Grossman said, "The risk factors for Coronary Disease include older age, diabetes, high blood pressure, smoking and a sedentary life style. Anyone from late teenagers to those in their 90s can experience cardiovascular disease, but it typically occurs in older Americans. Luckily, Medicare covers the Corus CAD test for patients with symptoms suggestive of obstructive CAD."
How is the test done?
"A patient's blood is drawn in the office, and one tube of blood is collected. The sample is then sent to the CardioDx lab in Palo Alto overnight. We receive the results within 48 hours, and then the patient returns to the office to discuss the findings."
This genomic blood test provides information about what's happening in your body right now.
• A blood test that measures the activity of specific genes in your blood that changes when there is a significant narrowing or blockage in your heart arteries, and can help your healthcare provider understand what may be causing your symptoms.
Please talk with your healthcare provider to find out if Corus CAD is right for you.
CardioDx®, a pioneer in the field of cardiovascular genomic diagnostics, is committed to improving the quality of care for patients with cardiovascular disease through the research, development, and validation of clinically important genomic tests that enable clinicians to better assess and individualize care for patients. The company is strategically focused on three cardiovascular disease areas: coronary artery disease, cardiac arrhythmia, and heart failure.
Deborah Kilpatrick, Chief Commercial Officer is part of the team that commercialized this test and she is delighted over the success. With more than 50,000 tests processed, Kilpatrick credits the company's success to the principle, "If you give talented people a chance to excel, they're likely to do just that."
Dr. Kirkpatrick is passionate about science and loves to speak about RNA, which is a key to understanding how Corus CAD works. She explained it in the following manner.
"DNA is like a light fixture and RNA relates to the level of light it produces like a dimmer switch that can go up or down. We measure RNA from white blood cells in your flowing blood associated with 23 “lights” (genes, DNA) whose “light levels” (expression of those genes) are up or down in patients presenting with symptoms that may be suggestive of obstructive CAD. It's well known that CAD is very much a disease associated with inflammation, and our clinical trials validating Corus CAD found this also. I am very proud to be a part of the team at CardioDx."
Thank you Dr. Grossman and Dr. Kilpatrick for sharing your experience with this innovative test that can find CAD early and in turn save many lives. Kilpatrick is also a co-founder of a group that will be highlighted in the future. She continues to be on the leading edge of Women's Health issues.